WTA: Players Undergoing Fertility Procedures to Get Protected Ranking
The new rule aims to support women athletes to balance their family goals and career ambitions and comes three months after the WTA offered players up to 12 months of paid maternity leave for the first time.
"The new rule means that players can now take time away from professional tennis for a fertility protection procedure such as egg or embryo freezing and safely return to competition with a protected ranking," the WTA said in a statement, according to Reuters.
"Eligible players will receive a Special Entry Ranking (SER), which can be used to enter up to three tournaments, based on the 12-week average of their WTA Ranking from eight weeks prior to the start of their out-of-competition period."
Sloane Stephens, the 2017 US Open champion, has previously called for egg freezing to be recognized as a protected ranking activity and called Wednesday's announcement a "ground-breaking" move.
"I'm incredibly proud of our sport in recognizing the importance of fertility treatments for female athletes. For any woman, the conversation of family life versus a career is nuanced and complex," the former world number three said.
"The WTA has now created a safe space for players to explore options and to make the best decisions for themselves."
The WTA also said players will benefit from paid maternity leave and grants for fertility protection through the WTA Maternity Fund.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Arab News
11 hours ago
- Arab News
Robert MacIntyre birdies last six holes to seize BMW Championship lead
OWINGS MILLS:Robert MacIntyre of Scotland birdied his last six holes to blow past Scottie Scheffler and grab the first-round lead of the BMW Championship on Thursday in Owings Mills, Md. For the latest updates, follow us @ArabNewsSport MacIntyre posted an 8-under-par 62 at Caves Valley Golf Club, which also hosted this tournament in 2021 and produced a plethora of low scores, including a 27-under winning mark for Patrick Cantlay. Nobody went lower than MacIntyre to open this year's edition. He will take a three-stroke lead over Englishman Tommy Fleetwood into Friday. Scheffler (4-under 66) is alone in third after taking the lead into the clubhouse in the day. MacIntyre entered the week 20th in the FedEx Cup standings. The top 30 after Sunday qualify for next week's Tour Championship, and a strong finish in Maryland would take MacIntyre far away from that bubble. The 29-year-old said he didn't believe a 62 was likely for anyone Thursday. 'There's chances. If you drive the ball well, it does give you chances,' MacIntyre said. .'.. I'm sure the next couple of days won't be as easy.' MacIntyre birdied the 11th hole but bogeyed the 12th to sit at 2 under for his round Thursday afternoon. His remarkable birdie run began with a 66-foot putt at the par-3 13th and a 40-footer at No. 14. In fact, the first five birdies of that streak all came from at least 11 feet out. At No. 18, he knocked his approach shot to inside 5 feet for the exclamation point. 'Probably the last six holes is probably as good as I've ever putted in a stretch of holes,' said MacIntyre, whose big moment this year was a runner-up finish at the US Open. 'Just so consistent.' Fleetwood's bogey-free 65 included a long putt of his own, a nearly 34-foot left-to-righter on the final hole to move past Scheffler for second. 'To go bogey-free around there is really, really good,' said Fleetwood. 'I think I made like two or three really good par saves, but apart from that, I did a lot of things well.' Fleetwood nearly captured his first PGA Tour victory last week at the FedEx St. Jude Championship but a late bogey kept him out of a playoff eventually won by countryman Justin Rose. There was a two-hour, 13-minute delay in the afternoon due to lightning in the area. When play resumed, Scheffler birdied three of his final four holes to set the early pace at 4-under 66. 'Significantly softer,' Scheffler said of how the course changed. 'The fairways were really rolling out to start the day. Greens were firm. So yeah, golf course changed pretty significantly after the delay.' Tied at 3-under 67 are Rickie Fowler, Ben Griffin and Norway's Viktor Hovland. Hovland, the 2023 BMW and FedEx Cup champion, needs a strong week to stay inside the top 30; he entered at No. 28. 'It's still another tournament,' Hovland said. 'I've still got to play well, and then we'll see how it shakes up. If I play halfway decent, that top 30 shouldn't be an issue. Just trying not to lose my mind out there if it goes south.' Fan favorite Fowler leapt from No. 64 to No. 48 by tying for sixth last week at the St. Jude. Another high finish could place him in the Tour Championship field for just the second time this decade. 'I feel like things have been heading in the right direction, and I've been in a good spot for a few months now of knowing where the game is and it's continuing to get better,' Fowler said. 'This (course) is a bit different. It's a lot different test than what Memphis gave us last week, but with how the game has been, in a way kind of playing the last two weeks — more so this week probably in a way, more so nothing to lose.'
Al Arabiya
12 hours ago
- Al Arabiya
Whoop refuses to disable blood pressure tool despite FDA warning
Whoop Inc., the maker of screen-less fitness bands, said it will not disable its blood-pressure tracking tool despite a request from the US Food and Drug Administration. The FDA last month sent a warning letter to Whoop stating that the company's Blood Pressure Insights feature, or BPI, which both measures blood pressure and provides related feedback, means that the Whoop is operating as a medical device. The new Whoop MG — short for medical grade — doesn't have such certification for blood pressure tracking despite intending to 'help with the diagnosis, cure or treatment of a disease,' according to the government agency. The band launched in May with the feature as a central addition. Whoop pushed back on the FDA's warning in a letter to the agency dated Aug. 4. 'We believe it is not within the FDA's authority to regulate the product. We therefore do not intend to remove the app,' the company wrote. 'We will continue to offer the wellness feature to consumers.' It added in a statement that it has 'requested a meeting with the FDA and hopes to have a constructive dialogue with agency officials.' On Thursday an FDA spokesperson said the agency 'has not authorized BPI for any use, including for the measurement or estimation of a user's blood pressure,' adding that 'patient safety is the FDA's highest priority.' FDA Versus Tech The FDA has clashed periodically over the last dozen years with technology companies whose devices the agency believes need regulation because they constitute medical advice. Still, Whoop's defiant reaction is rare. While regulators have struggled to define exactly when the line from wellness to medical advice is crossed, tech firms have often taken offending products off the market and sought FDA clearance or tweaked their product to comply. Meanwhile, consumer hardware makers have been adding more sophisticated health tracking tools to their fitness bands and smartwatches, blurring the lines between a wearable gadget and medical device. While the FDA can impose injunctions and fines on companies that fail to comply with violations raised in warning letters, it's rare that it follows through. The agency initially told Whoop that it should take 'prompt action' to address any violations or face potential regulatory action, including seizure, injunction and civil monetary penalties. The FDA also told Whoop it could go through the normal device approval process, something that Whoop doesn't want to do given the long amount of time that could take. Whoop said in its response that the feature is labeled for wellness purposes, not for diagnosing or treating medical conditions like hypertension. Whoop also said that repeated disclaimers are provided during the sign-up process. It characterized the issue as a 'misinterpretation' by the FDA, saying the agency views blood pressure estimation as a medical tool. The 'FDA's assertions fail to account for the substantial and growing body of scientific evidence supporting non-medical uses of blood pressure as well as the actual use of blood pressure information by the feature,' the company said in its response, which was provided to Bloomberg News. The Blood Pressure Insights feature lets users get a daily estimate of their blood pressure range so they can better understand the impact on overall health and athletic performance. The tool is available only to subscribers of the $359-a-year Whoop Life plan. The feature requires an initial calibration with a standard blood pressure cuff. Whoop Chief Executive Officer Will Ahmed previously called the FDA's letter 'misguided' on social media. The FDA said the product does not fall under the general wellness device policy because blood pressure it is not a low-risk use case. 'An erroneously low or high blood pressure reading can have significant consequences for the user,' it said in its July letter to the fitness startup. During an interview with Bloomberg TV on Thursday, Ahmed said he believes the company will be on the 'right side of history' and fighting for Americans' access to health data is the 'right thing to do.' 'Ultimately, innovation needs to be built to thrive in the United States,' he said. 'We're one of the first wearables that can measure blood pressure accurately on the wrist. That's a big deal. We want to make sure that there are policies that are consistent here in the US that really allow companies to innovate and to operate.' Other companies such as Garmin Ltd. offer FDA-cleared blood pressure reading tools. It's a feature also available on smartwatches from Samsung Electronics Co. Health and Human Services Secretary Robert F. Kennedy Jr. has promoted the use of wearable fitness devices. In an appearance before Congress in June, he said his vision is for every American to be using a wearable device within four years. Whoop CEO Ahmed was pictured meeting with Kennedy and other health tech companies in May.
Arab News
a day ago
- Arab News
Carmel Road heads to Taif for King Khalid Racecourse debut
TAIF: Carmel Road (USA) is poised to add a touch of spice to racing at King Khalid Racecourse this weekend when the former Bob Baffert inmate makes his Taif debut for trainer Bader Rizaiq. For the latest updates, follow us @ArabNewsSport The son of Quality Road was a big-money purchase by King Abdullah bin Abdulaziz and Sons from the Californian-based trainer, and after being set some stiff tasks in Riyadh last campaign he has his sights lowered for race three on the card — an open contest over 1400m. The mount of Fawaz Wannas was down the field in the 2024 Saudi Cup behind Senor Buscador (USA) and took 11th in The Custodian of the Two Holy Mosques Cup last January, and should find this test easier. He takes on familiar names, including Honky Tonk Man (IRE), which steps up in trip after his comeback run for jockey Nawaf Almudiani, trainer Hadi Gharawi, and owner Prince Faisal Bin Khaled Bin Abdulaziz, and recent open winner Ajwadi (GB) for in-form handler Thamer Aldaihani. Aljamaanee (KSA) returned to action with success at the end of last month for trainer Gaith Alghaith and now has his sights set on the main event this weekend. The JCSA Almaseef Cup Local Bred Horses Open is the feature race on Saturday and the Prince Saud Bin Salman Bin Abdulaziz-owned seven-year-old features among a field of 18 runners over 2000m after winning the prep for this on July 25. His chief rivals include the lightly raced Camilo Ospina-ridden Almaqam (KSA), while he will again clash with Katheer (KSA) for trainer Naif Alfadhel after the pair fought out the finish of the The Custodian of the Two Holy Mosques Cup for Apprentice Jockeys in January. Aldaihani also holds an excellent chance in the opening JCSA Sprint Cup Prep Local Bred Open on Saturday, with the Muhammad Aldaham-ridden Falah Zain (KSA) in the Sheikh Abdullah Homoud Almalek Alsabah colors clear on the figures. Ospina tops the jockeys' leaderboard following the first three weeks of action with nine wins and he has the plum ride on recent trial winner Nowafaa (KSA) who holds excellent claims for Rizaiq and White Stables in Friday's feature – the Taif Flower Festival Cup Local Bred Open. The race before that is the Um Alqura University Cup Open for Fillies and Mares in which the Ahmed Mohamoud-trained and Abdullah Alfairouz-ridden trial Aeadat (KSA) winner will head to post in a bid to try to stretch her winning sequence to nine. A close eye should also be kept on race four on Friday, with once-raced colts Kenzie (USA) for Ospina, Mohamoud and the White Stables taking on the also unbeaten Aeb Baad (USA), who remains with Alghaith but has been snapped up by the Red Stable of Prince Faisal.
